CD14 and cholangiocarcinoma: Study finds CD14-positive EVs are a novel biomarker of HCC and cholangiocarcinoma liquid biopsy that permit a non-invasive assessment of the presence and possible extent of these cancers in patients with advanced liver diseases (119).